Produktname:Ziconotide Acetate,Prialt
CAS-Registrierungsnummer: 107452-89-1
Molekulare Formel: C102H172N36O32S7
Molekulargewicht: 2639.01
Sequenz: Cys-Lys-Gly-Lys-Gly-Ala-Lys-Cys-Ser-Arg-Leu-Met-Tyr-Asp-Cys-Cys-Thr-Gly-Ser-Cys-Arg-Ser-Gly-Lys-Cys-NH2(Disfulde Bridge: 1-16, 8-20, 15-25)
Aussehen: Weißes Pulver
Grad: Pharmazeutische Qualität
Wassergehalt(Karl Fischer): 5.0%
Acetatgehalt(durch HPLC): 12.0%
Aminosäurezusammensetzung: 10% of theoretical
Reinheit(durch HPLC): 98.0%
Einzelne Verunreinigung(durch HPLC): 1.0%
Peptidgehalt(von %N ): 80%
Test(By Anhydrous, Acetic Acid-free ): 95.0~105,0 %
Lagerung: Cool(2~8 ) & dry place protected from light, keep package close when not in use.
Ziconotide (also known as SNX-111) is a neurotoxic peptide derived from the cone snail Conus magus comprising 25 amino acids with three disulphide bonds. Other such peptides, collectively termed conotoxins, exist, and some have shown efficacy in binding specific subsets of calcium channels; ziconotide is used in part because it can be synthesized without loss of proper bond formation or structural elements.Ziconotide is used to manage severe chronic pain refractory to other methods, through its ability to inhibit N-type calcium channels involved in nociceptive signalling.
Ziconotide is an N-type calcium channel antagonist used to manage patients with severe chronic pain who cannot tolerate, or who have not responded adequately to other treatments such as intrathecal morphine and systemic analgesics.
Ziconotide inhibits N-type calcium channels involved in nociceptive signalling, primarily in the dorsal horn of the spinal cord.Although binding is reversible, careful dosing is required to ensure therapeutic effects while minimizing adverse effects, and ziconotide has been described as possessing a narrow therapeutic window.Patients taking ziconontide may experience cognitive and neuropsychiatric symptoms, reduced levels of consciousness, and elevated serum creatine kinase levels. Zusätzlich, ziconotide may increase the risk of infection, including serious cases of meningitis. Patients who withdraw from opiates for ziconotide initiation are advised to taper off the dose.
